Related Experiment Video

Updated: Aug 29, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

[Future prospects in the management of cystic fibrosis]

I Pin1, C Pilenko, J P Gout

  • 1Département de pédiatrie, CHU de Grenoble, BP 217, 38043 Grenoble, France. IPin@chu-grenoble.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|December 16, 2003
PubMed

Insights

Research into cystic fibrosis (CF) explores new therapies due to incomplete understanding of the disease. Promising avenues include protein therapies and anti-inflammatory treatments, alongside strategies to combat bacterial infections.

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Microbiology

Background:

  • Cystic Fibrosis (CF) research seeks improved management strategies.
  • Current understanding of CF pathophysiology and optimal therapeutic targets remains incomplete.
  • Gene therapy for CF has faced significant limitations, necessitating research into alternative vectors.

Purpose of the Study:

  • To review emerging therapeutic strategies for cystic fibrosis.
  • To highlight advancements in protein-based therapies and anti-inflammatory approaches.
  • To discuss methods for preventing Pseudomonas aeruginosa colonization in CF patients.

Main Methods:

  • Review of current basic and clinical research in cystic fibrosis.
  • Analysis of novel therapeutic targets and approaches.
  • Synthesis of findings on gene therapy, protein therapy, anti-inflammatory agents, and anti-bacterial strategies.

Main Results:

  • Protein therapies, such as chaperone molecules activating mutated CFTR proteins, show promise.
  • New anti-inflammatory therapies, including protease inhibitors, are under development.
  • Strategies to prevent Pseudomonas aeruginosa infection, including vaccines and virulence factor inhibitors, are crucial.

Conclusions:

  • Multiple therapeutic avenues are being explored for cystic fibrosis.
  • Targeting mutated CFTR proteins and inflammation are key areas of focus.
  • Preventing bacterial infections is essential for improving patient outcomes in CF.

More Related Videos

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...